Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621126 | 0.93 | SLC6A4 (0.34) | SLC6A4IKBKBHTTSMN1; SMN2CDK2 | |
| SCHEMBL619228 | 0.90 | IKBKB (0.39) | SLC6A4IKBKB | |
| SCHEMBL621438 | 0.89 | IKBKB (0.40) | SLC6A4IKBKBKDM5BHTTSMN1; SMN2 | |
| SCHEMBL621437 | 0.86 | SLC6A4 (0.38) | SLC6A4KDM5BHTTSMN1; SMN2CDK2 | |
| SCHEMBL621127 | 0.84 | IKBKB (0.38) | SLC6A4IKBKBHTTSMN1; SMN2CDK2 | |
| SCHEMBL621367 | 0.83 | IKBKB (0.38) | SLC6A4IKBKB | |
| SCHEMBL621436 | 0.82 | SLC6A4 (0.38) | SLC6A4IKBKBKDM5BHTTSMN1; SMN2 | |
| SCHEMBL618891 | 0.80 | IKBKB (0.48) | IKBKB | |
| SCHEMBL10211426 | 0.80 | IKBKB (0.37) | SLC6A4IKBKB | |
| SCHEMBL619227 | 0.80 | IKBKB (0.48) | SLC6A4IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | SLC6A4 3971/4885IKBKB 8/4885KDM5B 535/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | SLC6A4 3980/4885IKBKB 8/4885KDM5B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.